| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
65,880,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on its T-win technology platform. Co.'s product candidates are designed to induce the immune system to simultaneously target and disrupt various pathways that regulate tumor-induced immunosuppression. Co.'s main product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. In addition to IO102, IO103 and IO112, Co. is evaluating additional candidates that have potential for use in solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
15,000 |
15,000 |
81,100 |
5,718,129 |
| Total Buy Value |
$20,885 |
$20,885 |
$75,761 |
$11,085,883 |
| Total People Bought |
1 |
1 |
5 |
8 |
| Total Buy Transactions |
1 |
1 |
5 |
9 |
| Total Shares Sold |
0 |
0 |
75,000 |
1,392,618 |
| Total Sell Value |
$0 |
$0 |
$99,126 |
$1,890,032 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
2 |
4 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hunter Heidi |
|
• • – |
2025-05-30 |
4 |
B |
$1.39 |
$20,885 |
D/D |
15,000 |
15,000 |
0.01 |
- |
|
| Zocca Mai-Britt |
Chief Executive Officer |
• • – |
2024-12-23 |
4 |
B |
$0.81 |
$10,120 |
D/D |
12,500 |
49,891 |
0.01 |
- |
|
| Smith Devin Whittemore |
General Counsel |
• • – |
2024-12-23 |
4 |
B |
$0.81 |
$9,720 |
D/D |
12,000 |
16,938 |
0.01 |
- |
|
| Sullivan Amy |
Chief Financial Officer |
• • – |
2024-12-23 |
4 |
B |
$0.83 |
$8,483 |
D/D |
10,250 |
84,632 |
0.01 |
- |
|
| Ahmad Qasim Iftikhar |
Chief Medical Officer |
• • – |
2024-12-23 |
4 |
B |
$0.85 |
$26,553 |
D/D |
31,350 |
31,350 |
0.01 |
- |
|
| Novo A/s |
|
– – • |
2024-07-26 |
4 |
S |
$1.31 |
$30,787 |
D/D |
(23,478) |
4,354,449 |
|
- |
|
| Novo A/s |
|
– – • |
2024-07-25 |
4 |
S |
$1.33 |
$68,339 |
D/D |
(51,522) |
4,377,927 |
|
- |
|
| Novo A/s |
|
– – • |
2024-05-10 |
4 |
S |
$1.22 |
$802,495 |
D/D |
(658,809) |
4,429,449 |
|
- |
|
| Novo A/s |
10% Owner |
– – • |
2024-02-09 |
4 |
S |
$1.50 |
$988,411 |
D/D |
(658,809) |
5,088,258 |
|
- |
|
| Burkavage Brian |
Chief Accounting Officer |
• • – |
2023-11-22 |
4 |
B |
$1.04 |
$5,175 |
D/D |
5,000 |
11,500 |
0.01 |
- |
|
| Burkavage Brian |
Chief Accounting Officer |
• • – |
2023-11-21 |
4 |
B |
$0.99 |
$4,950 |
D/D |
5,000 |
6,500 |
0.01 |
- |
|
| Kurma Partners |
|
– – • |
2023-08-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
6,821,133 |
|
- |
|
| Vivo Opportunity Fund Holdings, L.p. |
10% Owner |
– – • |
2023-08-09 |
4 |
B |
$1.90 |
$5,999,999 |
I/I |
3,157,894 |
3,157,894 |
1.5 |
- |
|
| Novo A/s |
10% Owner |
– – • |
2023-08-09 |
4 |
B |
$2.03 |
$4,999,998 |
D/D |
2,469,135 |
5,707,467 |
2.45 |
- |
|
| Lundbeckfond Invest A/s |
|
• • • |
2023-08-09 |
4 |
A |
$1.90 |
$15,012,345 |
D/D |
7,901,234 |
13,950,686 |
|
- |
|
| Elling Christian E |
|
• • • |
2023-08-09 |
4 |
A |
$1.90 |
$15,012,345 |
I/I |
7,901,234 |
13,950,686 |
|
- |
|
| Smith Devin Whittemore |
General Counsel |
• • – |
2023-08-09 |
4 |
A |
$1.90 |
$9,382 |
D/D |
4,938 |
4,938 |
|
- |
|
| Zocca Mai-Britt |
Chief Executive Officer |
• • – |
2023-08-09 |
4 |
A |
$1.90 |
$70,370 |
D/D |
37,037 |
37,391 |
|
- |
|
| Sullivan Amy |
Chief Financial Officer |
• • – |
2023-08-09 |
4 |
A |
$1.90 |
$93,826 |
D/D |
49,382 |
74,382 |
|
- |
|
| Sullivan Amy |
Chief Financial Officer |
• • – |
2023-03-17 |
4 |
B |
$2.32 |
$58,018 |
D/D |
25,000 |
25,000 |
0.01 |
- |
|
| Burkavage Brian |
Chief Accounting Officer |
• – – |
2022-05-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,500 |
|
- |
|
| Lundbeckfond Invest A/s |
|
• • • |
2021-11-09 |
4 |
B |
$14.00 |
$29,999,998 |
D/D |
2,142,857 |
6,049,452 |
0.01 |
- |
|
| Lundbeckfond Invest A/s |
|
• • • |
2021-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
3,906,595 |
3,906,595 |
|
- |
|
| Vivo Capital Fund Ix, L.p. |
|
• • • |
2021-11-09 |
4 |
B |
$14.00 |
$9,100,000 |
D/D |
650,000 |
3,015,545 |
0.01 |
- |
|
| Vivo Capital Fund Ix, L.p. |
|
• • • |
2021-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
2,365,545 |
2,365,545 |
|
- |
|
37 Records found
|
|
Page 1 of 2 |
|
|
